Breaking News Instant updates and real-time market news.

KDMN

Kadmon

$2.68

-0.04 (-1.47%)

08:08
11/06/18
11/06
08:08
11/06/18
08:08

Kadmon: KD033 inhibited tumor growth in models in study

Kadmon Holdings announced it will present preclinical data on KD033, its anti-PD-L1/IL-15 fusion protein in development for oncology indications, at the Society for Immunotherapy of Cancer Annual Meeting, taking place November 7-11, 2018, in Washington, D.C. KD033 is a novel immunotherapy designed to stimulate an immune response directed to the tumor microenvironment. Recombinant IL-15 alone, which stimulates cancer-fighting immune effector cells, is not well tolerated when administered systemically. Kadmon has developed a novel approach to overcome this challenge by fusing IL-15 to an anti-PD-L1 antibody to direct IL-15 activity specifically to the tumor microenvironment, promoting efficacy and inducing durable responses while potentially increasing tolerability. New data demonstrated that a single dose of KD033 inhibited tumor growth across multiple in vivo syngeneic tumor models and achieved dose-dependent efficacy in a resistant melanoma syngeneic mouse model. KD033 induced a strong immune memory response with a single treatment, resulting in mice that remained tumor-free following several tumor re-challenges. Furthermore, KD033 in combination with anti-PD1 therapy demonstrated synergistic activity, providing rationale for administering KD033 in combination with other immune checkpoint inhibitors. "Although immunotherapy has been game-changing for the treatment of cancer, many tumors learn to evade current therapies, limiting efficacy and durability of response. New approaches are needed to address relapsed or refractory patients as well as non-responders," said Harlan W. Waksal, M.D., President and CEO at Kadmon. "By directing a potent cancer-fighting response to the tumor site, KD033 has potential to safely overcome resistance and induce long-lasting responses for patients. We look forward to continuing our research on KD033 and initiating our first-in-patient studies in the second half of 2019."

  • 01

    Dec

KDMN Kadmon
$2.68

-0.04 (-1.47%)

12/21/17
JEFF
12/21/17
NO CHANGE
Target $9
JEFF
Buy
Kadmon Q1 data could bring 'significant' upside, says Jefferies
Jefferies analyst Biren Amin believes Kadmon's Phase II data for KD025 in chronic graft-versus-host disease, expected in Q1 of 2018, represent "significant" upside with little downside risk. KD025 has shown "encouraging activity" in a difficult to treat population, Amin tells investors in a research note. He assumes U.S. market entry of KD025 for treatment of chronic graft-versus-host disease in 2020 and estimates U.S. peak sales of 333.1M. The analyst has a Buy rating on Kadmon shares with a $9 price target.
02/13/18
JEFF
02/13/18
NO CHANGE
Target $16
JEFF
Buy
Kadmon price target raised to $16 from $9 at Jefferies
Jefferies analyst Biren Amin raised his price target for Kadmon Holdings to $16 after the company announced positive data on its Phase II trial of KD025 in idiopathic pulmonary fibrosis. The absolute improvement of 127 mL between arms surpasses the bar of 45-85 mL seen with existing therapies and the shares should react positively, Amin tells investors in a research note. He keeps a Buy rating on Kadmon shares.
02/13/18
PIPR
02/13/18
NO CHANGE
Target $9
PIPR
Overweight
Kadmon price target raised to $9 after data on KD025 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff noted that Kadmon announced "positive" topline Phase 2 data on KD025 in 29 evaluable idiopathic pulmonary fibrosis, or IPF, patients. Upon adding value for KD025 in IPF, the analyst increased his price target on Kadmon shares to $9 from $7 and reiterated his Overweight rating on the stock.
10/17/18
WBBS
10/17/18
UPGRADE
WBBS
Hold
Kadmon upgraded to Hold from Sell at WBB Securities

TODAY'S FREE FLY STORIES

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$278.60

0.71 (0.26%)

14:09
02/20/19
02/20
14:09
02/20/19
14:09
General news
'Almost all' Fed members wanted to announce plan to stop reducing assets »

Minutes from the last…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$278.60

0.71 (0.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$278.27

0.38 (0.14%)

14:06
02/20/19
02/20
14:06
02/20/19
14:06
General news
Fed saw 'variety of considerations' for 'patient approach to monetary policy' »

Minutes from the last…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$278.27

0.38 (0.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$278.32

0.43 (0.15%)

14:05
02/20/19
02/20
14:05
02/20/19
14:05
General news
Fed to continue monitoring economic developments for outlook implications »

Minutes from the last…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$278.32

0.43 (0.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$278.34

0.45 (0.16%)

14:02
02/20/19
02/20
14:02
02/20/19
14:02
General news
Fed sees 'sustained expansion of economic activity' as most likely outcome »

Minutes from the last…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$278.34

0.45 (0.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FDP

Fresh Del Monte

$29.97

0.7 (2.39%)

14:00
02/20/19
02/20
14:00
02/20/19
14:00
Hot Stocks
Breaking Hot Stocks news story on Fresh Del Monte »

Fresh Del Monte trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BHC

Bausch Health

$23.13

-2.04 (-8.10%)

14:00
02/20/19
02/20
14:00
02/20/19
14:00
Options
Dip buyer in Bausch Health Companies »

Dip buyer in Bausch…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 20

    Feb

  • 25

    Feb

  • 25

    Feb

  • 25

    Feb

  • 12

    Mar

  • 12

    Mar

VLKAY

Volkswagen

$0.00

(0.00%)

, AUDVF

Audi AG

$0.00

(0.00%)

13:59
02/20/19
02/20
13:59
02/20/19
13:59
Periodicals
Audi plans to cut 10% of management positions, Reuters reports »

Audi (AUDVF),…

VLKAY

Volkswagen

$0.00

(0.00%)

AUDVF

Audi AG

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TTD

Trade Desk

$146.31

-15.45 (-9.55%)

13:58
02/20/19
02/20
13:58
02/20/19
13:58
On The Fly
Trade Desk slides after analyst cuts rating ahead of quarterly results »

Shares of Trade Desk…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

  • 06

    Mar

  • 06

    Mar

UA

Under Armour

$19.15

-0.23 (-1.19%)

13:55
02/20/19
02/20
13:55
02/20/19
13:55
Options
Under Armour put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

  • 06

    Mar

PM

Philip Morris

$85.42

2 (2.40%)

13:50
02/20/19
02/20
13:50
02/20/19
13:50
Earnings
Philip Morris repeats Q1 reported diluted EPS view of $1.00, consensus $1.01 »

As communicated on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PM

Philip Morris

$85.42

2 (2.40%)

13:49
02/20/19
02/20
13:49
02/20/19
13:49
Earnings
Philip Morris reaffirms FY19 reported diluted EPS guidance of at least $5.37 »

Philip Morris…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:45
02/20/19
02/20
13:45
02/20/19
13:45
General news
Fed's Kaplan said a weaker business outlook is the reason for caution on rates »

Fed's Kaplan said a…

13:45
02/20/19
02/20
13:45
02/20/19
13:45
General news
Breaking General news story  »

FOMC Minutes to be…

MDR

McDermott

$7.80

0.44 (5.98%)

13:40
02/20/19
02/20
13:40
02/20/19
13:40
Options
Bullish option play in McDermott as shares rally ahead of earnings »

Bullish option play in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 25

    Feb

  • 04

    Mar

  • 05

    Mar

  • 12

    Mar

  • 17

    Mar

  • 18

    Mar

  • 02

    May

STAG

STAG Industrial

$28.24

-0.59 (-2.05%)

13:34
02/20/19
02/20
13:34
02/20/19
13:34
Recommendations
STAG Industrial analyst commentary  »

STAG Industrial price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$1,118.00

-0.16 (-0.01%)

, GOOGL

Alphabet Class A

$1,125.12

-1.31 (-0.12%)

13:28
02/20/19
02/20
13:28
02/20/19
13:28
Periodicals
Epic Games stops 'Fortnite' pre-roll ads on YouTube due to predators, Verge says »

Epic Games is no longer…

GOOG

Alphabet

$1,118.00

-0.16 (-0.01%)

GOOGL

Alphabet Class A

$1,125.12

-1.31 (-0.12%)

TCEHY

Tencent

$0.00

(0.00%)

DIS

Disney

$113.63

0.11 (0.10%)

KKR

KKR

$23.52

-0.2 (-0.84%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 25

    Feb

  • 27

    Feb

  • 03

    Mar

  • 07

    Mar

  • 18

    Mar

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$278.00

0.11 (0.04%)

13:28
02/20/19
02/20
13:28
02/20/19
13:28
Periodicals
Barr could announce end of Mueller investigation next week, CNN reports »

Attorney General Bill…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$278.00

0.11 (0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OMI

Owens & Minor

$6.40

-1.54 (-19.40%)

13:24
02/20/19
02/20
13:24
02/20/19
13:24
Periodicals
Owens & Minor working with banks to explore sale, Reuters reports »

Owens & Minor is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

OMI

Owens & Minor

$6.41

-1.53 (-19.27%)

13:20
02/20/19
02/20
13:20
02/20/19
13:20
Hot Stocks
Breaking Hot Stocks news story on Owens & Minor »

Owens & Minor trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

OMI

Owens & Minor

$6.41

-1.53 (-19.27%)

13:18
02/20/19
02/20
13:18
02/20/19
13:18
Hot Stocks
Breaking Hot Stocks news story on Owens & Minor »

Owens & Minor halted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

GOLD

Barrick Gold

$13.98

0.43 (3.17%)

13:17
02/20/19
02/20
13:17
02/20/19
13:17
Hot Stocks
Barrick Gold confirms commitment to Chile as it reviews LATAM strategy »

The company said,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OMI

Owens & Minor

$6.41

-1.53 (-19.27%)

13:17
02/20/19
02/20
13:17
02/20/19
13:17
Periodicals
Breaking Periodicals news story on Owens & Minor »

Owens & Minor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
02/20/19
02/20
13:17
02/20/19
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$161.80

-0.49 (-0.30%)

, GOOG

Alphabet

$1,114.63

-3.53 (-0.32%)

13:16
02/20/19
02/20
13:16
02/20/19
13:16
On The Fly
#SocialStocks: YouTube updates penalty system, Twitter developing Snapchat-like camera »

Welcome to…

FB

Facebook

$161.80

-0.49 (-0.30%)

GOOG

Alphabet

$1,114.63

-3.53 (-0.32%)

GOOGL

Alphabet Class A

$1,121.14

-5.29 (-0.47%)

TWTR

Twitter

$31.37

-0.27 (-0.85%)

SNAP

Snap

$9.17

-0.11 (-1.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 25

    Feb

  • 25

    Feb

  • 03

    Mar

  • 18

    Mar

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
02/20/19
02/20
13:16
02/20/19
13:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.